| abstract |
The present invention relates to pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to mammals, particularly humans, suffering from diseases and disorders related to androgen receptor (AR), especially cancer, and more particularly Prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, chemotherapy-treated metastatic castration-resistant prostate cancer, biochemically recurrent hormone-sensitive prostate cancer, or high-risk non-metastatic castration resistance Prostate cancer. In one aspect, the formulations include abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from the group consisting of HPMCAS, poly (meth) acrylate copolymers, and mixtures thereof. In one aspect, the formulations include particles of abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from the group consisting of HPMCAS, poly (meth) acrylate copolymers, and mixtures thereof. |